Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transparency Initiative In "What Is The Right Thing To Do" Phase - Sharfstein

This article was originally published in The Tan Sheet

Executive Summary

In June, FDA launched an internal Transparency Task Force to evaluate how to make the agency's decision-making process more accessible to the public. The agency held two public meetings and solicited comments; the docket closed Nov. 6. FDA Principal Deputy Commissioner Joshua Sharfstein, who chairs the task force, spoke to Elsevier Business Intelligence's "The Pink Sheet" about its initial findings.

You may also be interested in...



FDA's Policy On Releasing More Drug Application Material Coming Soon

The drug industry should have a better idea by the end of February how far FDA might go in releasing information currently withheld from the public, including complete response letters, withdrawn applications and other similar material

FDA's Policy On Releasing More Drug Application Material Coming Soon

The drug industry should have a better idea by the end of February how far FDA might go in releasing information currently withheld from the public, including complete response letters, withdrawn applications and other similar material

FDA's Policy On Releasing More Drug Application Material Coming Soon

The drug industry should have a better idea by the end of February how far FDA might go in releasing information currently withheld from the public, including complete response letters, withdrawn applications and other similar material

Related Content

UsernamePublicRestriction

Register

PS103585

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel